Author + information
- Received August 17, 2017
- Accepted August 31, 2017
- Published online January 30, 2018.
- aDivision of Cardiology, Medstar Washington Hospital Center, Washington, DC
- bMedstar Heart and Vascular Institute, Washington, DC
- cDepartment of Oncology, Georgetown University, Washington, DC
- ↵∗Address for correspondence:
Dr. Ana Barac, Medstar Heart and Vascular Institute, 110 Irving Street Northwest, Suite 1F1218, Washington, DC 20010.
Contemporary cancer therapies have dramatically improved cancer-free and overall survival but have been accompanied by increasing cancer treatment–related cardiovascular toxicity, including left ventricular (LV) systolic dysfunction. Previously, systemic chemotherapy with anthracyclines and radiation therapy were the only cancer treatments with significant cardiotoxicity. However, modern targeted cancer therapies, including HER2 inhibitors, tyrosine kinase inhibitors (TKIs), proteasome inhibitors, and immune checkpoint inhibitors, have all been associated with adverse cardiovascular events. As cancer treatment paradigms successfully move toward prolonged targeted therapy, cardiologists are increasingly needed to assess cardiotoxicity risk and manage asymptomatic and symptomatic LV systolic dysfunction. This state of the art review summarizes the present knowledge about the mechanisms and clinical practices of screening, diagnosis, and management of LV dysfunction associated with cancer therapeutic regimens. We utilize the framework of the ACCF/AHA stages of heart failure (HF) to summarize current evidence for risk stratification and modification (Stage A HF), asymptomatic structural heart disease detection and treatment (Stage B HF), and reduction of HF morbidity and mortality (Stages C and D HF) during cancer treatment and in survivorship. We also present new clinical practice challenges and opportunities for active engagement of cardiologists with multidisciplinary cancer treatment teams in order to ensure optimal patient outcomes.
Dr. Barac is the cardiology principal investigator on the SAFE-HEaRt trial supported by Genentech, Inc., but has received no financial support for this role. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received August 17, 2017.
- Accepted August 31, 2017.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.